Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
AstraZeneca
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Pfizer
M.D. Anderson Cancer Center
Alterome Therapeutics, Inc.
M.D. Anderson Cancer Center
Hoffmann-La Roche
Astellas Pharma Inc
Quanta Therapeutics
Dana-Farber Cancer Institute
Treeline Biosciences, Inc.
R-Pharm
Pfizer
Incyte Corporation
Chugai Pharmaceutical
Tizona Therapeutics, Inc
Genentech, Inc.
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
Pfizer
Boehringer Ingelheim
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Pfizer
Chugai Pharmaceutical
Quanta Therapeutics
Incyte Corporation
City of Hope Medical Center
Bristol-Myers Squibb
Fate Therapeutics
Fate Therapeutics
University of Chicago
C4 Therapeutics, Inc.
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Quanta Therapeutics
University of Chicago
University of California, San Diego
University of Colorado, Denver
Innovent Biologics (Suzhou) Co. Ltd.
Pfizer
Celgene